CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TheSlowLane who wrote (181)	6/25/1997 2:44:00 AM
From: Miljenko Zuanic	of 675

To all: From June 25, BioCentury Extra: Reason for trials data independent analyst concern: "Dr. Gamzu speculated that a great proportion of adverse events in the Cerestat group (didn't mentioned arm separately) versus the placebo group has been detected by the analysis." Correction for lower dose: 3mg bolus followed by 0.5mg/hr for 12 hr (not 48hr). This lower dose is equal as 110mcg/kg weight-adjusted dose that show improvement in stroke patients. "Interim stroke data did not warrant suspension of the TBI trial (15 mg bolus followed by 3mg/hr over three days." Because the interim data analysis are mainly for adverse events, I am speculating that lower dose arm will show acceptable profile of the safety and efficiency, and the trials will continue with this dose. Good time for CNSI position star/add to position. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next